[131I]metaiodobenzylguanidine treatment of a malignant paraganglioma.
The bone metastases of a malignant, non-secreting paraganglioma were treated with [131I]metaiodobenzylguanidine (131I-MIBG) over a 10-year period. Initial treatment (131I-MIBG: 9.6 GBq) resulted in a decrease in the number of bone metastases from 16 to 2. At three years, a relapse with primary tumor regrowth and liver metastasis was again treated with 131I-MIBG (22.2 GBq). A decrease in the number of bone metastases and MIBG uptake was again observed.
Baulieu
J L
JL
Service de Médecine Nucléaire, Hôpital Bretonneau, Tours, France.
Guilloteau
D
D
Calais
G
G
Lefloch
O
O
Besnard
J C
JC
D019797:3-Iodobenzylguanidine; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D010235:Paraganglioma / Q000556:secondary* / Q000628:therapy; D011877:Radionuclide Imaging
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine